Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary MATEON THERAPEUTICS AND ABIOGENESIS TO INITIATE CLINICAL STUDY TO TEST ARTEMISININ AS A TREATMENT FOR COVID-19 IN INDIA
AGOURA HILLS, Calif. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, will be working together with Abiogenesis to initiate ARTI-19 randomized, controlled, multi-site India clinical study of Artemisinin against COVID-19.
View HTML
Toggle Summary Mateon Therapeutics Closes $2.0 Million Financing
AGOURA HILLS, Calif. , July 27, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB: MATN) announced the closing of the 1 st tranche of financing related to the Mateon operations and spinoff of its EdgePoint AI, Inc. (“EdgePoint”, a Delaware Corporation and a division of Mateon).  JH Darbie & Co.,
View HTML
Toggle Summary Mateon and Asili Research Alliance Enter Into Partnership for the Development of Artemisinin Against Covid-19
AGOURA HILLS, Calif. , July 20, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today the launch of its global observational study called ARTI-19, for Artemisinin Intervention against COVID-19, in partnership with Asili Research
View HTML
Toggle Summary Mateon Therapeutics to fund observational studies of Artemisinin in developing countries
AGOURA HILLS, Calif. , July 13, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today that it will fund observational studies for Artemisinin, an herbal supplement, that demonstrated potent in vitro activity against SARS-CoV-2, the
View HTML
Toggle Summary Company expands its management team to accelerate the commercialization and development of OT-101 for COVID-19
-   Stonegate Capital Partners Initiates Coverage on Mateon Therapeutics (MATN). Agoura Hills, California , July 09, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB: MATN) , a late-stage biotechnology company developing Trabedersen (OT-101), a TGF-β inhibitor with the potential for multiple
View HTML
Toggle Summary Mateon Therapeutics Appoints Dr. Anthony Maida as Chief Clinical Officer - Translational Medicine
Company expands its management team to accelerate the evaluation of OT-101 for Oncology and COVID-19 Agoura Hills, California , July 07, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB: MATN) , a late-stage biotechnology company developing Trabedersen (OT-101), a TGF-β inhibitor with the
View HTML
Toggle Summary MATEON ANNOUNCES $2 MILLION FINANCING WITH GOLDEN MOUNTAIN PARTNERS TO CONDUCT CLINICAL TRIAL OF OT-101 AGAINST COVID19
AGOURA HILLS, Calif. , June 29, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announces it has secured a $2 million in debt financing with Golden Mountain Partners (GMP) for the conduct of a clinical trial evaluating OT-101 against COVID-19.
View HTML
Toggle Summary Mateon is Selected by IBM Watson Health for the Use of IBM Clinical Development Solution at No Cost for Phase II Clinical Trial of OT-101 for COVID-19
Mateon was approved to use the platform following a review of the program as part of IBM Watson Health’s effort to help support and accelerate promising clinical COVID-19 candidates AGOURA HILLS, Calif. , June 24, 2020 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of
View HTML
Toggle Summary Mateon Therapeutics Selects IQVIA for its Randomized, Controlled, Multi-Center Clinical Study to Test OT-101 as a Treatment for COVID-19 Patients
AGOURA HILLS, Calif. , June 23, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, has selected IQVIA to manage C001, a Phase 2 randomized, controlled, multi-center clinical study of OT-101. This study is designed to evaluate the safety,
View HTML
Toggle Summary Mateon and GMP Completed Research and Service Agreement
Mateon and GMP to proceed to clinical development of OT-101 and Artemisin and other antisense drug candidates against COVID-19 AGOURA HILLS, Calif. , June 22, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”)  (OTCQB:MATN) announces that both Golden Mountain Partners
View HTML